InBioGen Co Ltd

InBioGen's capital structure is characterized by a low debt-to-equity ratio of 0.01, indicating minimal leverage, and a current ratio of 2.86, suggesting strong short-term liquidity. The company's price-to-book ratio of 0.5 and price-to-tangible-book ratio of 0.5 reflect a significant discount to its book value, potentially signaling undervaluation or underlying asset impairment. However, the company's negative operating cash flow of -5.55 billion KRW and free cash flow of -1.098 billion KRW highlight liquidity constraints despite its strong current ratio. Profitability metrics are severely negative, with a return on equity of -0.9% and return on assets of -0.89%, both well below industry norms. The company's operating income of -5.385 billion KRW and net income of -1.419 billion KRW indicate substantial operational losses. These figures contrast sharply with the industry's preferred metrics, which typically emphasize positive returns and stable margins. InBioGen's revenue is spread across four segments: Kiosk Business, Footwear Business, Wood Pellet Business, and Other Business. The Kiosk Business is the primary revenue driver, but the company's financial snapshot does not provide specific revenue contributions by segment. The geographic exposure is not detailed, but the company's operations are likely concentrated in South Korea, given its ticker symbol and business activities. The company's growth trajectory is negative, with a net income of -1.419 billion KRW and a gross profit of -347.32 million KRW. The outlook for the current fiscal year is not provided, but the negative operating and free cash flows suggest a challenging environment. The company's recent financial performance indicates a need for significant operational improvements to achieve profitability. Risk factors include medium liquidity risk due to negative net cash after subtracting total debt. The company's dilution risk is low, with no near-term pressure expected. However, the negative operating cash flow and free cash flow could necessitate future financing, potentially leading to dilution. The risk assessment also notes the need for close monitoring of liquidity metrics. Recent events include the company's transition from BTOne Co Ltd to InBioGen Co Ltd, reflecting a strategic shift in business focus. The company's recent financial filings show a last actual EPS of -360.00 KRW, indicating ongoing financial challenges. No recent transcripts or significant events are disclosed that would suggest a turnaround in the near term.